173 related articles for article (PubMed ID: 17272984)
21. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
Li J; Mookerjee B; Wagner J
J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
[TBL] [Abstract][Full Text] [Related]
22. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
23. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
Grange JM; Krone B; Stanford JL
Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for immunotherapy in hepatocellular carcinoma?
Zerbini A; Pilli M; Ferrari C; Missale G
Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
[TBL] [Abstract][Full Text] [Related]
26. Melanoma vaccines: developments over the past 10 years.
Klein O; Schmidt C; Knights A; Davis ID; Chen W; Cebon J
Expert Rev Vaccines; 2011 Jun; 10(6):853-73. PubMed ID: 21692705
[TBL] [Abstract][Full Text] [Related]
27. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
28. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma.
Gottlieb DJ; Micklethwaite K; Bradstock KF; Li YC
Cytotherapy; 2007; 9(2):133-43. PubMed ID: 17453965
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of melanoma.
Rietschel P; Chapman PB
Hematol Oncol Clin North Am; 2006 Jun; 20(3):751-66. PubMed ID: 16762733
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cell immunotherapy for stage IV melanoma.
O'Rourke MG; Johnson MK; Lanagan CM; See JL; O'Connor LE; Slater GJ; Thomas D; Lopez JA; Martinez NR; Ellem KA; Schmidt CW
Melanoma Res; 2007 Oct; 17(5):316-22. PubMed ID: 17885587
[TBL] [Abstract][Full Text] [Related]
31. Melanoma treatment update.
Tsao H; Sober AJ
Dermatol Clin; 2005 Apr; 23(2):323-33. PubMed ID: 15837158
[TBL] [Abstract][Full Text] [Related]
32. Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton D; Eilber FR; Malmgren RA; Wood WC
Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
[TBL] [Abstract][Full Text] [Related]
33. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
34. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
35. Melanoma vaccines.
Riley LB; Agarwala SS
Expert Rev Vaccines; 2008 Sep; 7(7):937-49. PubMed ID: 18767944
[TBL] [Abstract][Full Text] [Related]
36. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
[TBL] [Abstract][Full Text] [Related]
37. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
[TBL] [Abstract][Full Text] [Related]
38. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
39. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
40. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
